Aghemo A - Search Results

1

Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C.

Rumi M, Aghemo A, Prati GM. Rumi M, et al. Among authors: aghemo a. J Viral Hepat. 2012 Jan;19 Suppl 1:37-41. doi: 10.1111/j.1365-2893.2011.01525.x. J Viral Hepat. 2012. PMID: 22233412 Review.

2

US features of liver surface nodularity as a predictor of severe fibrosis in chronic hepatitis C.

Viganò M, Visentin S, Aghemo A, Rumi MG, Ronchi G. Viganò M, et al. Among authors: aghemo a. Radiology. 2005 Feb;234(2):641; author reply 641. doi: 10.1148/radiol.2342041267. Radiology. 2005. PMID: 15671013 No abstract available.

3

The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies.

Monti V, Aghemo A, Rumi MG, Donato MF, Del Ninno E, Colombo M. Monti V, et al. Among authors: aghemo a. Antivir Ther. 2005;10(6):715-20. Antivir Ther. 2005. PMID: 16218170 Clinical Trial.

4

The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.

Rumi MG, D'Ambrosio R, Aghemo A. Rumi MG, et al. Among authors: aghemo a. J Hepatol. 2006 Apr;44(4):825; author reply 825-6. doi: 10.1016/j.jhep.2006.01.022. Epub 2006 Feb 9. J Hepatol. 2006. PMID: 16513204 No abstract available.

5

Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.

Aghemo A, Rumi MG, Soffredini R, D'Ambrosio R, Ronchi G, Del Ninno E, Gallus S, Colombo M. Aghemo A, et al. Antivir Ther. 2006;11(6):797-802. Antivir Ther. 2006. PMID: 17310824

6

Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study.

Rumi MG, Aghemo A, D'Ambrosio R, Ronchi G, Del Ninno E, Gallus S, Colombo M. Rumi MG, et al. Among authors: aghemo a. Antivir Ther. 2007;12(7):1033-40. Antivir Ther. 2007. PMID: 18018761

7

Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection.

Taliani G, Rucci P, Biliotti E, Cirrincione L, Aghemo A, Alberti A, Almasio PL, Bartolozzi D, Caporaso N, Coppola R, Chiaramonte M, Floreani A, Gaeta GB, Persico M, Secchi G, Versace I, Zacharia S, Mele A. Taliani G, et al. Among authors: aghemo a. J Viral Hepat. 2007 Dec;14(12):875-82. doi: 10.1111/j.1365-2893.2007.00883.x. J Viral Hepat. 2007. PMID: 18070291

8

Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics?

Aghemo A, Rumi MG, Colombo M. Aghemo A, et al. J Viral Hepat. 2008 Jun;15(6):471. doi: 10.1111/j.1365-2893.2008.00975.x. Epub 2008 Mar 6. J Viral Hepat. 2008. PMID: 18331249 No abstract available.

9

Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism.

Bersano A, Aghemo A, Rumi MG, Ballabio E, Candelise L, Colombo M. Bersano A, et al. Among authors: aghemo a. Eur J Intern Med. 2008 Jul;19(5):370-1. doi: 10.1016/j.ejim.2007.10.003. Epub 2007 Nov 28. Eur J Intern Med. 2008. PMID: 18549943

10

The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: should we utilize more?

Aghemo A, Rumi MG, Prati GM, Colombo M. Aghemo A, et al. Hepatology. 2009 Feb;49(2):702-3; author reply 703-4. doi: 10.1002/hep.22732. Hepatology. 2009. PMID: 19177585 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

354 results

Search Page

Filters